Study of Enfuvirtide in HIV-Positive Subjects

Trimeris

Status and phase: Completed; Phase 1

Conditions: AIDS; HIV Infections

Treatments: Drug: Fuzeon

Study type: Interventional

Funder types: Industry

Identifiers

NCT00086710

T20-405

Details and patient eligibility

About

A total of 26 patients will be admitted to the clinic where they will be dosed with each injection device. There will be a 7-day washout between doses and a 7-10 day follow-up period.

Sex: All

Ages: 18 to 64 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Exclusion criteria

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Crossover Assignment

Masking: None (Open label)